Mirae Asset Global Investments’s Esperion Therapeutics ESPR Stock Holding History

Mirae Asset Global Investments’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36.4K	Sell	11,513 -956	-8%	-$2.67K	﹤0.01%	1411
2026 Q1	$34.2K	Buy	12,469 +852	+7%	+$2.7K	﹤0.01%	1360
2025 Q4	$43K	Buy	11,617 +3,822	+49%	+$12.3K	﹤0.01%	1430
2025 Q3	$20.7K	Buy	7,795 +139	+2%	+$269	﹤0.01%	1487
2025 Q2	$7.54K	Buy	7,656 +1,260	+20%	+$1.26K	﹤0.01%	1521
2025 Q1	$9.59K	Sell	6,396 -170	-3%	-$313	﹤0.01%	1474
2024 Q4	$15K	Buy	+6,566	New	+$15.3K	﹤0.01%	1461
2023 Q1	–	Sell	-26,267	Closed	-$164K	–	2550
2022 Q4	$164K	Buy	26,267 +204	+0.8%	+$1.46K	﹤0.01%	2345
2022 Q3	$174K	Buy	26,063 +8,044	+45%	+$55.2K	﹤0.01%	2385
2022 Q2	$114K	Buy	+18,019	New	+$102K	﹤0.01%	2283
2015 Q4	–	Sell	-47,500	Closed	-$1.12M	–	463
2015 Q3	$1.12M	Buy	47,500 +25,480	+116%	+$1.6M	0.05%	279
2015 Q2	$1.8M	Buy	22,020 +6,590	+43%	+$645K	0.06%	224
2015 Q1	$1.43M	Buy	+15,430	New	+$996K	0.05%	251

Other funds holding ESPR

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Mirae Asset Global Investments's ESPR Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Esperion Therapeutics (ESPR) stake by 7.7% in Q2 2026, selling an estimated $2.67K and leaving 11,513 shares worth $36.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1411.

Mirae Asset Global Investments first reported a position in ESPR in Q1 2015 and has held it in 13 quarters since. The position peaked at $1.8M in Q2 2015. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Mirae Asset Global Investments held 11,513 shares of Esperion Therapeutics worth $36.4K as of Q2 2026.
Mirae Asset Global Investments sold 956 Esperion Therapeutics shares in Q2 2026, an estimated $2.67K.
Esperion Therapeutics made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1411 holding.
Mirae Asset Global Investments first reported a position in Esperion Therapeutics in Q1 2015 and has held it in 13 quarters since.
Mirae Asset Global Investments's Esperion Therapeutics position peaked at $1.8M in Q2 2015.
192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.